SEPN
Septerna, Inc.
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2024-10-25
$43.70
+0.50 (+1.16%)
last quote
Want the full multi-source brief on SEPN?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$43.70
High
$44.58
Low
$42.22
Previous close
$43.20
Fundamentals
Market cap
$2.02B
P/E (TTM)
—
P/S (TTM)
20.39x
P/B
3.27x
Gross margin
—
Operating margin
-44.04%
Net margin
-24.51%
Rev growth (YoY)
13520.11%
EPS growth (YoY)
—
ROE
-6.31%
52W high
$51.10
52W low
$17.55
Beta
1.04x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-25in 20 days
Q3 2026EPS est $-0.42Rev est $21.2M
Recent SEC filings
CIK 1984086filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 23h
Septerna to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences before the end of 2026: Guggenheim 3rd Annual Healthcare Innovation Conference – BostonFireside chat on Tu
Yahoo · 6d
Is Septerna (SEPN) Stock Too Rich, Or Still Reasonable?
Septerna has delivered a sharp share-price run over the past year, and that leaves investors asking whether the current market value is adequately grounded in its sales. With the stock now drawing more attention, the key issue is how much revenue the business is actually producing to back up that enthusiasm. Septerna has returned 97.8% over the past year, which puts a lot of weight on the question
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial